Until now, key terms used to describe CIDP management were not uniformly defined. What it meant to “respond to treatment,” “relapse,” or reach “remission” had often been left to individual physicians, ...

Learn about switching from IVIg to SCIg for CIDP, including benefits, barriers, and support for home-based subcutaneous ...

Learn how pain is managed in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including medications, therapies, procedures, and lifestyle strategies.

CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients were ...

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase 3 ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy ...